Carlo Sorrentino
Chieti, 66100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 21, 2025
Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.
Journal: Molecular biomedicine
Published: August 25, 2025
State of the art CRISPR-based strategies for cancer diagnostics and treatment.
Journal: Biomarker research
Published: September 20, 2024
Oxidative Stress and Age-Related Tumors.
Journal: Antioxidants (Basel, Switzerland)
Published: July 19, 2024
Prevention of prostate cancer metastasis by a CRISPR-delivering nanoplatform for interleukin-30 genome editing.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 10, 2024
The multifaceted role of the stroma in the healthy prostate and prostate cancer.
Journal: Journal of translational medicine
Published: April 12, 2024
Immunoliposome-based targeted delivery of the CRISPR/Cas9gRNA-IL30 complex inhibits prostate cancer and prolongs survival.
Journal: Experimental & molecular medicine
Published: February 05, 2024
Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.
Journal: Journal of experimental & clinical cancer research : CR
Published: July 24, 2023
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.
Journal: Cancers
Published: May 05, 2023
Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.
Journal: Journal for immunotherapy of cancer
Published: February 27, 2023
Last Updated: 09/26/2026